Shares of Waldencast PLC (NASDAQ:WALD – Get Free Report) have received an average recommendation of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $4.4167.
Several brokerages have commented on WALD. Weiss Ratings reiterated a “sell (e+)” rating on shares of Waldencast in a research report on Wednesday, January 21st. Jefferies Financial Group started coverage on Waldencast in a research report on Wednesday, January 14th. They set a “buy” rating and a $2.00 price target on the stock. Canaccord Genuity Group decreased their price target on shares of Waldencast from $5.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, November 25th. Finally, Telsey Advisory Group downgraded shares of Waldencast from an “outperform” rating to a “market perform” rating and set a $3.00 price objective on the stock. in a research report on Tuesday, November 25th.
Read Our Latest Research Report on WALD
Institutional Inflows and Outflows
Waldencast Price Performance
Shares of NASDAQ WALD opened at $1.80 on Monday. The company has a current ratio of 1.53, a quick ratio of 0.67 and a debt-to-equity ratio of 0.32. Waldencast has a twelve month low of $1.45 and a twelve month high of $3.54. The business has a 50 day simple moving average of $1.80 and a 200-day simple moving average of $1.88.
Waldencast (NASDAQ:WALD – Get Free Report) last released its quarterly earnings results on Monday, November 24th. The company reported ($0.69) EPS for the quarter. The firm had revenue of $66.14 million for the quarter. Analysts expect that Waldencast will post -0.14 EPS for the current year.
About Waldencast
Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians. The company also offers clean makeup products under the Milk Makeup brand. It sells its products to dermatologists, plastic surgeons, and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force, as well as through distribution partners.
See Also
- Five stocks we like better than Waldencast
- This $15 Stock Could Go Down as the #1 Stock of 2026
- I’m 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)
- America’s 1776 happening again
- Trump & Musk’s Secret Bet on Silver — Exposed
- Your Bank Account Is No Longer Safe
Receive News & Ratings for Waldencast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waldencast and related companies with MarketBeat.com's FREE daily email newsletter.
